{"id":"NCT01508702","sponsor":"Ardea Biosciences, Inc.","briefTitle":"Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors","officialTitle":"A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2013-10","completion":"2013-11","firstPosted":"2012-01-12","resultsPosted":"2016-02-12","lastUpdate":"2016-02-12"},"enrollment":214,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Gout"],"interventions":[{"type":"DRUG","name":"lesinurad","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"lesinurad 400 mg","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the serum uric acid lowering effects and safety of lesinurad compared to placebo in patients who are intolerant or have a contraindication to allopurinol or febuxostat.","primaryOutcome":{"measure":"Number of Subjects With an sUA Level That is < 6.0 mg/dL","timeFrame":"6 months","effectByArm":[{"arm":"Lesinurad 400 mg","deltaMin":32,"sd":null},{"arm":"Placebo","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":106,"countries":["United States","Australia","Belgium","Canada","Germany","New Zealand","South Africa"]},"refs":{"pmids":["35835008","29029210"],"seeAlso":["http://www.gouttrial.com"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":107},"commonTop":["Diarrhoea","Blood creatinine increased","Bronchitis","Constipation","Cough"]}}